Making the switch from LHRH antagonist to LHRH agonist
Author:
Publisher
Springer Science and Business Media LLC
Subject
Urology
Link
http://www.nature.com/articles/nrurol.2012.5.pdf
Reference10 articles.
1. Garnick, M. B. & Mottet, N. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist. BJU Int. http://dx.http://dx.doi.org/10.1111/j.1464-410X.2011.10708.x .
2. McLeod, D. et al. A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology 58, 756–761 (2001).
3. Mongiat-Artus, P. & Teillac, P. Abarelix: the first gonadotrophin-releasing hormone antagonist for the treatment of prostate cancer. Expert Opin. Pharmacother. 5, 2171–2179 (2004).
4. Klotz, L. et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 102, 1531–1538 (2008).
5. Crawford, E. D. et al. A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer. J. Urol. 186, 889–897 (2011).
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Lipid Membrane-Wrapped Zeolitic Imidazolate Framework-8 for Synergistic Chemotherapy and Photothermal Therapy to Target Prostate Cancer;Journal of Biomedical Nanotechnology;2022-08-01
2. Accuracy of serum luteinizing hormone and serum testosterone measurements to assess the efficacy of medical castration in prostate cancer patients;Journal of Biomedical Science;2017-10-22
3. Treatment Patterns and Trends in Patients Dying of Prostate Cancer in Quebec: A Population-Based Study;Current Oncology;2017-08-01
4. Gonadotropin-releasing hormone antagonists versus standard androgen suppression therapy for advanced prostate cancer A systematic review with meta-analysis;BMJ Open;2015-11-13
5. Drug costs in the management of metastatic castration-resistant prostate cancer in Canada;BMC Health Services Research;2014-06-13
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3